Case series of intravenous ketamine infusion in patients with suicidal thought

Suicide is the fourth leading cause of death. The annual global prevalence of suicidal ideas in adult population is 2%. Antidepressants are considered to be the first line of treatment for depression but the maximum response is noted only after 4-6 weeks. However, adding ketamine has shown very rapid response (within hours) and high remission rates in patients with depression. Here, we present case series of five depressive patients on treatment with antidepressants having suicidal thoughts. All participants received ketamine infusion 0.5 mg/kg over 45 min at a weekly interval as add-on treatment to ongoing treatment. The responses were assessed by using Montgomery Åsberg Depression Rating Scale psychometric tool. The finding indicates that ketamine infusion had a rapid, antisuicidal effect and is safe when used for a short period.